Small Molecule Protein-Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles

被引:145
作者
Blazer, Levi L. [1 ]
Neubig, Richard R. [1 ,2 ,3 ]
机构
[1] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med, Ctr Chem Genom, Ann Arbor, MI 48109 USA
关键词
protein-protein interaction; RGS; small molecule; PDZ; amyloid-beta; a-synuclein; AMYLOID-BETA AGGREGATION; ENDOGENOUS RGS PROTEINS; SYSTEM DRUG TARGETS; G184S GNAI2 ALLELE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; NEURODEGENERATIVE DISEASES; SUSCEPTIBILITY GENE; PDZ-DOMAIN;
D O I
10.1038/npp.2008.151
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Protein-protein interactions are a crucial element in cellular function. The wealth of information currently available on intracellular-signaling pathways has led many to appreciate the untapped pool of potential drug targets that reside downstream of the commonly targeted receptors. Over the last two decades, there has been significant interest in developing therapeutics and chemical probes that inhibit specific protein-protein interactions. Although it has been a challenge to develop small molecules that are capable of occluding the large, often relatively featureless protein-protein interaction interface, there are increasing numbers of examples of small molecules that function in this manner with reasonable potency. This article will highlight the current progress in the development of small molecule protein-protein interaction inhibitors that have applications in the treatment or study of central nervous system function and disease. In particular, we will focus upon recent work towards developing small molecule inhibitors of amyloid-beta and alpha-synuclein aggregation, inhibitors of critical components of G-protein-signaling pathways, and PDZ domain inhibitors.
引用
收藏
页码:126 / 141
页数:16
相关论文
共 160 条
[71]  
Jin Y, 2004, METHOD ENZYMOL, V389, P266
[72]  
Johnston TH, 2006, CURR OPIN INVEST DR, V7, P25
[73]  
Johnston Tom H, 2004, Curr Opin Investig Drugs, V5, P720
[74]   Signal transduction molecules at the glutamatergic postsynaptic membrane [J].
Kennedy, MB .
BRAIN RESEARCH REVIEWS, 1998, 26 (2-3) :243-257
[75]   The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Gα-interaction face [J].
Kimple, Adam J. ;
Willard, Francis S. ;
Giguere, Patrick M. ;
Johnston, Christopher A. ;
Mocanu, Viorel ;
Siderovski, David P. .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2007, 1774 (09) :1213-1220
[76]   Cortical stabilization of β-catenin contributes to NHERF1/EBP50 tumor suppressor function [J].
Kreimann, E. L. ;
Morales, F. C. ;
de Orbeta-Cruz, J. ;
Takahashi, Y. ;
Adams, H. ;
Liu, T-J ;
McCrea, P. D. ;
Georgescu, M-M .
ONCOGENE, 2007, 26 (36) :5290-5299
[77]   The emerging role of PDZ adapter proteins for regulation of intestinal ion transport [J].
Lamprecht, G. ;
Seidler, U. .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2006, 291 (05) :G766-G777
[78]   A point mutation in Gαo and Gαi1 blocks interaction with regulator of G protein signaling proteins [J].
Lan, KL ;
Sarvazyan, NA ;
Taussig, R ;
Mackenzie, RG ;
DiBello, PR ;
Dohlman, HG ;
Neubig, RR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (21) :12794-12797
[79]   ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures [J].
Landau, M ;
Mayrose, I ;
Rosenberg, Y ;
Glaser, F ;
Martz, E ;
Pupko, T ;
Ben-Tal, N .
NUCLEIC ACIDS RESEARCH, 2005, 33 :W299-W302
[80]   RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia [J].
Lane, Hsien-Yuan ;
Liu, Yi-Ching ;
Huang, Chieh-Liang ;
Chang, Yue-Cune ;
Wu, Po-Lun ;
Huang, Chiung-Hsien ;
Tsai, Guochuan E. .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (01) :64-68